A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Famitinib Malate
Sponsor: Fudan University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.